Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: MARCKSL1–2 reverses docetaxel-resistance of lung adenocarcinoma cells by recruiting SUZ12 to suppress HDAC1 and elevate miR-200b

Fig. 1

Down-regulation of lncRNA MARCKSL1–2 is associated with DTX resistance and poor prognosis in LAD patients. a MARCKSL1–2 expression was detected by RT-qPCR in the DTX sensitive- (CR + PR; n = 28) and insensitive- (SD + PD; n = 32) LAD tissues. b MARCKSL1–2 expression in normal lung tissues (n = 20) and LAD tissues (n = 60) was determined by RT-qPCR. c Kaplan-Meier analysis of the association between progression-free survival (PFS) and MARCKSL1–2 level in LAD patients. d Kaplan-Meier analysis of the association between overall survival (OS) and MARCKSL1–2 level in LAD patients. e RT-qPCR tested the expression of MARCKSL1–2 in DTX-resistant LAD cells relative to parental H1299 or SPC-A1 cells. f-g Subcellular fractionation analyzed MARCKSL1–2 distribution in LAD cells and matched DTX-resistant cells. h IF analysis of MARCKSL1–2 distribution in parental and DTX-resistant LAD cells. Scale bar = 20 μm. **P < 0.01

Back to article page

Molecular Cancer

ISSN: 1476-4598